Hair Relaxer Lawsuit: Updates and Settlements (September 2025)

A study published in the Journal of the National Cancer Institute reveals that people who use chemicals to straighten or relax their hair have a higher risk of developing uterine cancer. Women of color, especially Black women, often use these products to style their naturally curly or wavy hair. 

As a result, these women face the greatest chance of receiving a cancer diagnosis, according to the study. Women who regularly use chemical hair relaxers are twice as likely to develop uterine cancer as those who do not. Many women facing medical issues after using these products are filing hair straightener cancer lawsuits against various product manufacturers.

Relaxers and straighteners use a combination of chemicals to break down each hair's structure and make it more pliable and soft. People who prefer a smoother style often use these products several times yearly to maintain the look. 

Chemical Hair Relaxers Linked to Uterine Cancer

Unfortunately, these products are now linked to an increased risk of uterine cancer, especially for those who have regularly used relaxers and straighteners for a long time. There are now several published scientific studies linking hair relaxers to cancer.

Suppose doctors diagnosed you or a loved one with uterine cancer, and you used hair relaxers or chemical hair straightening products in the past. In that case, you may be eligible to bring a product liability lawsuit against the manufacturer of the products you used.

If successful, you could receive financial compensation from the hair care product manufacturers that didn't warn you about the dangers of using their products.

To learn more about your legal rights, consult a hair relaxer lawyer with significant experience handling product liability claims. The Lawsuit Legal News team was founded by top-rated Attorney Matthew Dolman. When you contact our team, you can trust us to answer your questions and explain your possible legal options. Reach out today for a free consultation.

Chemical Hair Relaxers Lawsuit Updates

Please check back here regularly. This will be the most up-to-date page regarding hair relaxer litigation.

We will continue to provide updates on the hair relaxer cancer lawsuit, which has been consolidated into a multidistrict litigation (MDL) in the Northern District of Illinois before Judge Mary Rowland. We anticipate that thousands of new lawsuits against chemical hair straighteners will still be filed over the coming year.

This should continue to be one of the fastest-growing mass torts. The hair relaxer lawsuit is powerful as L'Oreal USA has a significant market share. There is a growing body of scientific research and published studies linking uterine cancer to hair relaxer use. More scientific literature continues to be published on the toxic chemicals in hair relaxer products.

Furthermore, our lawyers believe that chemical hair straightener brands have long been aware that the endocrine-disrupting chemicals in their products, such as phthalates, metals, and parabens, are known carcinogens (chemicals that cause cancer). 

Because brands such as L'Oreal failed to provide a warning that the use of such products could cause uterine cancer, they should be held responsible for the medical conditions their users now face. The link between hair relaxers and uterine cancer is powerful.

Here are the latest developments in the hair straightener uterine cancer lawsuits:

September 1, 2025 - 5 Plaintiffs Dismissed, New Filings Grow, Revlon Can’t Have Requested Documents

Judge Mary Rowland dismissed five plaintiffs from the federal hair relaxer multidistrict litigation (MDL) for failing to file their required Short Form Complaints by the court’s August 14 deadline. The dismissals were entered “with prejudice,” meaning these plaintiffs cannot refile their claims.

While any dismissal might raise concern, legal experts note that procedural enforcement helps preserve the integrity of the litigation. Removing plaintiffs who cannot meet filing requirements ensures the docket remains focused on viable, well-documented cases and helps streamline progress toward resolution for those actively pursuing claims.

New Lawsuit Filed by Connecticut Woman Diagnosed with Uterine Cancer

A new complaint filed in the MDL alleges that nearly 40 years of hair relaxer use contributed to a woman’s diagnosis of uterine cancer in 1988. The Connecticut resident claims she began using relaxers before 1980 and continued until about 2020.

The lawsuit targets several major defendants, including L’Oréal, Revlon, SoftSheen-Carson, and Strength of Nature, and cites products like Dark and Lovely, Just for Me, and Revlon Realistic. The complaint includes causes of action for design defect, failure to warn, fraudulent concealment, and more, along with a demand for punitive damages.

MDL Adds 285 New Cases in July

The hair relaxer MDL continues to grow, now totaling 10,567 cases, up from 10,282 the previous month. The uptick reflects both new filings and continued administrative refinement, including dismissals and consolidations. 

Many plaintiffs are just now connecting their cancer diagnoses, such as uterine, ovarian, or endometrial cancer, to long-term use of chemical hair straighteners. The latent nature of these conditions, along with ongoing awareness campaigns, is likely contributing to the continued stream of new claims.

While bellwether trials (test cases) have not yet been scheduled, the MDL is expected to enter expert discovery and general causation challenges in the coming months.

Judge Denies Revlon’s Attempt to Access NIH Internal Files

Judge Rowland recently denied Revlon’s attempt to subpoena internal records from the National Institutes of Health (NIH), marking a procedural win for plaintiffs.

Revlon had sought access to unpublished materials, including work papers, drafts, and correspondence between NIH researchers and plaintiffs' attorneys, in an effort to challenge the studies linking chemical hair relaxers to cancer. The NIH objected, citing the deliberative process privilege, and the court agreed, ruling that Revlon had not met the standard required to override protections afforded to non-party government agencies.

The ruling reinforces the court’s focus on published science and limits speculative attacks on the underlying research.

Revlon remains an active defendant in the MDL despite its 2023 bankruptcy restructuring. Its liability is now tied to insurance policies, which are expected to fund any potential settlements or judgments in these claims.

August 1, 2025 - Pressure Grows With More Cases Filed and Science Day Scheduled

L’Oréal Ordered to Hand Over European Safety Files

The pressure continues to build on major hair relaxer manufacturers, especially L’Oréal.

A federal magistrate judge has ordered L’Oréal SA to turn over a collection of European safety documents for products sold in the U.S. These Product Information Files (PIFs) are required by EU law and contain detailed information about product formulas, safety testing, and manufacturing processes.

So far, L’Oréal was to produce 19 files covering 29 hair relaxer formulas by July 31. Additional documents related to products sold only overseas are due by September 12, after both sides meet to determine which ones are most important.

These files could be critical to the case. U.S. safety regulations for cosmetics are notoriously weak compared to Europe’s. If these EU-mandated files reveal internal safety concerns, untested ingredients, or double standards in how products were formulated for international markets, it could seriously harm the defense.

Don’t Expect a Settlement Any Time Soon

Although thousands of women have now joined the lawsuit, a global settlement is still a long way off.

The court hasn’t scheduled any bellwether trials yet. And without the pressure of a trial looming, the companies involved, including L’Oréal, Strength of Nature, and Dabur, have little incentive to negotiate.

Legal experts say the turning point will likely come after the judge rules on expert challenges. These rulings determine what scientific evidence juries will hear and often set the stage for serious settlement talks. That won’t happen until late 2026, at the earliest.

In short: the litigation is still strong, but moving slowly.

“Science Day” Set for January 2026

To help the court understand the medical side of these claims, a science day has been scheduled for January 8, 2026.

Science days are common in mass tort cases. They allow both sides to present educational overviews of the science behind the claims, without cross-examination or formal testimony. It’s a way for the judge (and possibly other judges from related state court cases) to learn about the research linking chemical hair relaxers to reproductive cancers, fibroids, and hormonal disruption.

Plaintiffs’ experts will present in the morning, and defense experts will go in the afternoon. The information shared won’t be binding, but it will likely influence the judge’s views on the reliability and relevance of the science going forward.

MDL Case Count Drops Slightly—But New Claims Still Being Filed

As of this update, the Hair Relaxer MDL includes 10,282 cases, a slight dip from last month’s total of 10,317. That decrease is likely due to ongoing case review and consolidation, not a lack of interest.

In fact, new lawsuits continue to be filed as more women connect the dots between their hormone-related diagnoses and long-term use of chemical straighteners. Because cancers like uterine and ovarian cancer often develop years after exposure, many potential plaintiffs are just now discovering the link.

This litigation is still active and growing. Lawyers are now focused on expert discovery, corporate documents, and laying the scientific foundation that will shape the upcoming trials—likely starting in late 2026 or early 2027.

July 1, 2025 - Walgreens Dismissed, Federal and State Cases Grow

Walgreens Dropped from Hair Relaxer Lawsuits

A federal judge has dismissed the only hair relaxer lawsuit that named Walgreens as a defendant. The case involved a woman whose sister died from uterine cancer after buying hair relaxers from Walgreens. However, the judge ruled the lawsuit was too vague because it only referenced a single purchase in 2010 and failed to show that Walgreens made any promises or knew about the cancer risks.

This decision confirms what many lawyers in the MDL already concluded: Walgreens is unlikely to play a major role in this litigation.

Dozens of Hair Relaxer Cases Grouped in Philadelphia

Pennsylvania has officially launched a new mass tort program for hair relaxer lawsuits. At least 25 cases have already been grouped together in Philadelphia’s Complex Litigation Center, which will handle them on a single mass tort docket.

Our lawyers expect many more filings in Philadelphia. The city is known for handling big, dangerous product cases like Roundup and Paraquat, and it offers plaintiffs a favorable venue with experienced judges and juries known to take corporate misconduct seriously.

Similar state court groupings are underway in Georgia and New York, in addition to the main federal MDL we are following in Illinois.

Georgia Court to Decide: Can You Still Sue After 10 Years?

Georgia’s highest court is reviewing a critical legal issue: Should women be allowed to sue if more than 10 years have passed since their first use of a chemical relaxer?

Under Georgia’s “statute of repose,” claims may be blocked if the first sale of the product happened more than a decade ago—even if the cancer didn’t show up until much later.

This is a big deal because hormone-related diseases like uterine cancer often take years to appear. Lawyers argue that the law should account for repeated use over time, especially when companies keep selling the same harmful products to the same consumers.

First Trials in Sight as MDL Gains Momentum

The federal Hair Relaxer MDL is heading toward its first trials. Judge Mary Rowland has issued a detailed schedule to identify the first group of plaintiffs whose cases will be heard in court. These “bellwether” trials will help shape the future of the entire litigation.

Here’s what’s ahead:

Date	Key Event
Oct. 31, 2025	Plaintiffs name expert witnesses linking relaxers to reproductive cancers
Dec. 1, 2025	Defense reveals its expert reports
Dec. 15, 2025	Plaintiffs respond to defense experts
Mar. 2, 2026	All expert discovery must be completed
Apr. 1, 2026	Both sides file Daubert motions to challenge expert testimony
May 1–15, 2026	Briefs and replies on Daubert challenges

These early stages will begin in late 2025 and continue into 2026, with full trials likely kicking off in early 2027.

No Settlement Yet—but Discovery Is Revealing

Although some observers hoped for a fast settlement, that’s not in the cards yet. Both sides are still deep in discovery, exchanging documents and expert reports.

The first trials are expected to focus on plaintiffs with uterine, ovarian, and endometrial cancers. These conditions were linked to hair relaxers by major studies like the NIH Sister Study.

What’s most striking so far is what hasn’t been found in corporate records: no safety testing, warnings, or internal analysis of the long-term risks. That lack of action could end up being more damaging than any internal memo.

A major settlement likely won’t happen until the court rules on expert challenges in mid-2026.

Hair Stylists Have Some of the Strongest Cases

Some of the most compelling lawsuits are being filed by hairstylists and salon professionals. These women spent years working closely with hair relaxers, mixing, applying, and inhaling the chemicals for hours a day.

That daily exposure over the years makes their cases especially strong. Studies show the more you're exposed, the higher your cancer risk. And legally, the long-term exposure helps prove the connection between the product and illness.

Importantly, unlike consumers, stylists had no realistic way to avoid these exposures. And manufacturers never warned them about the risks.

MDL Case Numbers Rise Slowly, State Courts Add Pressure

The number of cases in the federal MDL grew slightly last month, from 10,168 to 10,317. That’s a slower pace than earlier this year, but filings continue across the country.

Meanwhile, state court litigation is gaining steam, especially in Philadelphia, where judges can move faster than their federal counterparts. Lawyers say the state court system there offers more flexibility and a better chance of early trials.

Philadelphia juries are also known for taking consumer safety seriously, making it an appealing battleground in the fight against companies like L’Oréal and Strength of Nature.

June 1, 2025 - Hair Relaxer Lawsuits Move Forward as Discovery Intensifies

The Hair Relaxer MDL continues to grow and evolve, with over 10,000 lawsuits now pending from women who developed uterine, ovarian, or endometrial cancer after years of using chemical straighteners. In May 2025, the litigation advanced on several fronts, underscoring both the complexity of the case and the potential risks for the companies involved.

Discovery Phase in Full Swing

Judge Mary Rowland has ordered both sides to submit detailed updates on discovery progress. Thirty-two cases involving reproductive cancers are being used to shape the bellwether trial pool. Fact discovery is scheduled to run through February 2026, with general causation evidence due by March 2026. Although the first trial likely won’t begin before mid-2027, depositions and document production are now underway. One sticking point has been the production of foreign regulatory materials by L’Oréal USA—an issue the court continues to monitor closely.

L’Oréal SA Dismissed—but Core Defendants Remain

While the French parent company, L’Oréal SA, was recently dismissed from the MDL for lack of personal jurisdiction, this does not impact the heart of the litigation. The core defendants—including L’Oréal USA, Strength of Nature, and Dabur—remain fully involved and financially capable of paying any damages that may result from settlements or verdicts.

Settlement Outlook

A special master was appointed in April to help manage potential settlement talks. While this is standard in MDLs of this size, it does not mean settlement is imminent. So far, no breakthrough has been reported. Plaintiffs continue to highlight the lack of corporate oversight and safety testing, which, combined with scientific studies linking these products to cancer, could increase legal exposure. Most legal experts believe that meaningful settlement negotiations likely won’t occur until late 2025 or early 2026, after key rulings on expert evidence.

May 1, 2025–Discovery Efforts, Bellwether Trials, and Class Action Updates

L’Oréal USA – one of the key defendants – filed an unopposed motion seeking international judicial assistance to obtain evidence from its French parent company, L’Oréal S.A. The motion, filed under the Hague Convention on Evidence, asks the court to help compel L’Oréal’s France-based affiliate to turn over documents needed for discovery. This step underscores the ongoing evidence-gathering phase, as defendants and plaintiffs seek internal company records about product ingredients, testing, and health effects.

Bellwether Trial Selection. Progress is being made toward selecting bellwether trials in the multidistrict litigation (MDL). By April 30, 2025, plaintiffs and defendants must each submit a list of 20 representative cases they believe are strongest for their side​. From this pool of 40 cases, the court will pare down to 32, ultimately choosing 10 bellwether cases for early trials. (Only cases involving uterine, endometrial, or ovarian cancer diagnoses are eligible for this bellwether pool​.) These first trials are scheduled for 2026 and will serve as test cases; their outcomes are expected to inform settlement negotiations and legal strategy for the thousands of remaining claims.

State and Other Actions. No significant state-court hair relaxer lawsuit developments were reported in the past month. (Most individual suits have been removed to federal court and absorbed into MDL 3060.) In a related aspect of the litigation, a proposed consumer class action seeking economic damages, including refunds for product purchases and medical monitoring, continues to proceed alongside the injury cases. Last fall, Judge Rowland largely denied a motion to dismiss that class action, allowing claims that manufacturers misled consumers about product safety to move forward​. That class action is also pending in the MDL, though it has not seen new rulings in the last 30 days.

April 1, 2025–The Deadline for Bellwether Cases Approaches

As of April 2025, significant developments have occurred in the litigation concerning chemical hair relaxers and their alleged links to cancer and other health issues. Below is a comprehensive overview of the latest lawsuit filings, court rulings, medical studies, and regulatory actions from the past 30 days.

Lawsuit Filings and Court Rulings

• Multidistrict Litigation (MDL) Progress. The consolidated MDL for hair relaxer lawsuits continues to evolve. Parties must propose bellwether cases by April 30, 2025, a critical step in selecting representative cases for early trials. These bellwether trials will provide insight into how juries may respond to evidence and potentially influence settlement discussions.
• Recent Case Dismissals. In January 2025, Judge Mary Rowland of the U.S. District Court for the Northern District of Illinois dismissed 112 cases without prejudice due to plaintiffs' failure to submit required fact sheets or respond to deficiency letters. This action underscores the importance of adhering to procedural requirements in the MDL process.

Bellwether Trials and Settlement Negotiations

• Bellwether Trial Selection. The process of selecting bellwether cases is underway, with plaintiffs and defendants identifying representative cases to proceed to early trials. These trials are anticipated to commence in late 2025 or early 2026 and are expected to significantly influence the direction of the litigation, including potential settlement negotiations.

Medical Studies and Health Concerns

• Expanded Health Risks. Recent studies have reinforced concerns about the safety of chemical hair relaxers. Beyond the previously established links to uterine and ovarian cancers, new research indicates potential associations with other health issues, such as breast cancer and respiratory damage. These findings highlight the need for consumers to be aware of the broader health risks associated with these products.
• Synthetic Hair Products. Emerging research has identified carcinogenic chemicals in synthetic hair used for braiding, including lead in certain products. This discovery raises additional health concerns for individuals using these hair styling methods.

Hair relaxer litigation is rapidly evolving, with significant legal, medical, and regulatory developments occurring in the past month. As the MDL progresses and new health studies emerge, affected individuals and stakeholders should remain informed about these changes. Those impacted by chemical hair relaxers should consult with legal and medical professionals.

Earlier Hair Relaxer Lawsuit News

Throughout this litigation, the defendants have resisted providing important documents and caused procedural delays while lawyers for the injured plaintiffs have tried to push their cases toward trial or settlement. Of course, during these proceedings, more women are being diagnosed with cancer or, even worse, dying from cancer, which they link to using hair straightening products. 

The defendants have filed motions to dismiss class claims and plaintiffs’ requests for punitive damages. The court denied these motions so the possibility of a punitive damage award against these hair product makers is still viable and could prove to be costly for the injuries these companies may have caused. 

[/faq_block]

Why You Should Choose Lawsuit Legal News to Help With Your Lawsuit

We are proud to have earned numerous distinctions on our way to being a nationally recognized, award-winning personal injury legal team. We are dedicated to helping clients whose defective products have harmed.

Our hair relaxer attorneys provide over 120 years of combined experience in product liability to advocate for clients suffering serious, complicated injuries and losses. We'll use our knowledge and skills to help you prepare and present a solid product liability case to recover the losses you deserve.

The Dolman Law Group has represented over 10,000 victims of negligence and has collected over $500 million in compensation on behalf of our clients. Matthew Dolman is an experienced attorney who has been repeatedly selected by his colleagues as one of Florida's Legal Elite and a Florida Superlawyer multiple times.

Matthew has been active in the hair straightener class action lawsuit since the beginning. The hair relaxer lawyers at Dolman Law Group have studied the harmful chemicals in these hair relaxer and hair straightener products. We are well versed in the health conditions associated with the dangerous chemicals in hair straighteners, including phthalates, phenols, and paragons.

More specific chemicals in hair relaxers include formaldehyde, sodium hydroxide, and lye are known carcinogens (i.e., chemicals that can cause cancer when one is exposed to them in sufficient quantity).

When you speak with one of our product liability lawyers, we can explain whether you can take legal action, who you can hold responsible, the damages you can request, and how the process works.

Our goal is to help you recover the compensation you need to put your life back in order and hold negligent manufacturers responsible for the injuries their products cause.

We believe that manufacturers such as L'Oreal knew full well just how dangerous their chemical straighteners were and failed to warn prospective consumers.

How Our Product Liability Lawyers Can Help you File a Lawsuit

To join this MDL, all injured plaintiffs must prepare and file a Short Form Complaint and comply with the legal procedures required by the MDL judge. If you have questions about bringing a hair product claim, consult an experienced product liability lawyer affiliated with Lawsuit Legal News (LLN). Our team can:

• Explain the complicated legal process,
• Help you gather and prepare the necessary evidence required to support your claim,
• Help you decide whether to file a civil lawsuit or join the multi-district litigation (MDL) now pending in Illinois and
• Fight for your rights to receive the compensation you deserve.

We are actively investigating hair straightener injury claims against several different manufacturers. We understand the profound impact a cancer diagnosis can have on the lives of countless consumers, and we are prepared to fight for you.

How Can You Hold Product Manufacturers Responsible for Causing Cancer?

The U.S. Food and Drug Administration regulates cosmetics and other products sold in our country. Manufacturers must make cosmetics safe for consumers who follow the label instructions or customary procedures for using the product. Hair care products must meet rigorous safety standards to be safe, effective, and not dangerous to society.

Consumers who purchase hair products have the right to expect that these treatments will not harm them or cause an increased risk of cancer. Hair straightening product manufacturers are legally obligated to provide safe hair products and warn about cancer-causing ingredients. Suppose a manufacturer fails to market a safe product or warn about its potential dangers. In that case, you can bring a claim to hold it responsible for paying compensation for the injuries its product caused. 

If a dangerous product injures you, turn to a nationally recognized and award-winning law firm that understands what you are facing. Our team of product liability and mass tort lawyers has advocated for many injured consumers and filed numerous product liability lawsuits against manufacturers that create and sell items that harm users.

If you have developed uterine cancer after using hair straightening or relaxing products, don't wait to contact the team of product liability lawyers at LLN and Dolman Law Group to discuss your right to file a lawsuit.

Recent Studies Show a Connection Between Uterine Cancer and Hair Straightener Use

The Journal of the National Cancer Institute (JNCI) published a study analyzing the relationship between hair straightening and relaxing products and the occurrence of uterine cancer among consumers. The researchers followed 33,947 participants from The Sister Study.

The Sister Study tracked almost 51,000 women from 2003 to 2009. The participants were women ages 35 to 74 who were breast cancer-free at the start of the study but had at least one sister who was diagnosed with breast cancer. Through questionnaires and self-reporting, the study analyzed thousands of women, the products they used over several years, and the cancer incidence among the group.

The researchers involved in the JNCI study noted:

“In the Sister Study, we have previously observed a higher breast cancer incidence associated with adolescent and adult use of hair products and a higher ovarian cancer incidence associated with adult use of straighteners.” Citations omitted.

A study by the International Journal of Cancer reported possible links between products such as hair straighteners and hair dyes and the development of breast and ovarian cancers. So, although hair products have been controversial for a long time because of their chemical makeup and the harm they can cause, no one has looked for a link to uterine cancer until now.

The JNCI study examined Sister Study data provided by roughly 33,500 women who met the qualifications for the program. These women reported using several different hair products, including hair straighteners, relaxers, hair color, permanents, body waves, and other hair modifying products.

Finding a Statistical Link Between Uterine Cancer and Chemical Hair Straighteners

Of the 33,497 participants in the JNCI study, 378 women reported a uterine cancer diagnosis. The results indicated that only 1.64 percent of women who reported they never used hair straightening products developed uterine cancer by age 70. However, 4.05 percent of women in the study who used chemical hair straighteners or relaxers developed uterine cancer by age 70.

The study also found that women who used chemical hair straighteners within the prior year had a higher risk of developing uterine cancer than those who had never used these products. In an even more frightening finding, women who reported using chemical hair straighteners four or more times in the past year suffered an even higher risk of uterine cancer.

The Science Behind the Hair Relaxer Lawsuit

Overall, uterine cancer is relatively rare. Although the number of women reporting a cancer diagnosis appears low, these statistics show a sizable increase in cancer risks linked to using chemical hair straighteners. Also, this study uncovers an ethnic bias against Black women because more Black women use hair straighteners than Caucasian women, usually from an early age. Unfortunately, uterine cancer is more common in Black women, and Black women are more likely to die from uterine cancer than other ethnicities.

The study participants who used hair straighteners were diagnosed with uterine cancer more than twice as often as those who never used straighteners. Considering the large number of women involved in this study, these findings may link thousands of uterine cancer cases to hair product use.

The Scary Lack of Government Regulation of Beauty Products

The lack of federal oversight regarding the safety of beauty products like hair relaxers leaves consumers dangerously in the dark. The Fair Packaging and Labeling Act does require manufacturers to list ingredients on product labels, but significant gaps exist—many of which put people's health at risk.

One big problem is the lack of rules to make everything clear. For instance, chemicals grouped as "fragrance" or "flavor" don't need to be listed individually, letting harmful things like phthalates stay off labels. Phthalates, often tied to hormone problems and an increased risk of cancer, can be in these products without buyers ever knowing.

A 2018 study by the Silent Spring Institute looked at 18 hair care products often sold to Black women and found worrying results. The researchers spotted dozens of EDCs or endocrine-disrupting chemicals, and many of these have links to health problems like cancer. What's even more concerning is that 84% of the harmful ingredients they found in these products weren't listed on the packaging.

This lack of transparency and oversight lets companies sneak dangerous chemicals into their products without telling customers. Hair relaxer lawsuits are now bringing attention to this problem, which could lead to changes in laws and rules. But until stricter laws come into effect, customers are still at risk, often not knowing the complete list of chemicals in their products.

Hair Relaxer Uterine Cancer FAQs

Uterine Cancer Basics and the Harm You May Suffer

Uterine cancer falls into two types—Type 1 endometrial cancer is more common, while Type 2 uterine sarcoma is more rare. Doctors can often cure this cancer in the early stages by performing a hysterectomy or other surgery. Other treatments, such as immunotherapy and chemotherapy, may work, depending on the type and severity of the cancer.

Uterine cancer patients experience similar symptoms, procedures, and challenges as other cancer patients, including:

• Surgery involving risks, pain, and extended recovery.
• Chemotherapy with strong drugs to destroy cancer cells. 
• Radiation using targeted beams that burn and destroy cancer cells. 
• Hormone replacement therapy, since the condition involves the reproductive system. Patients might receive hormones to replace what the body can no longer create or to block further cancer growth.
• Medicine therapy focusing on keeping certain types of cancer cells from growing.
• Immunotherapy to stimulate the patient’s natural immune system to fight cancer.

These treatments often make the patient nauseous and unable to eat. Certain chemicals can also reduce the patient's ability to fight off other diseases or conditions, such as pneumonia or the common cold. 

Uterine cancer patients may also face:

• Skin burns from radiation, 
• Reactions to medications, 
• The inability to perform basic daily activities,
• Loss of employment, 
• Extensive and long-term medical care and rehabilitation,
• Mental and emotional distress and 
• Death.

Since most uterine cancer victims have surgeons remove their uterus, they can no longer bear children and will probably start menopause regardless of their age. These circumstances create another group of physical and emotional repercussions beyond the typical issues faced by cancer survivors.

You Can Afford to Partner With Lawsuit Legal News

The lawyers behind Lawsuit Legal News strive to help those injured by ruthless corporations that care more about their bottom lines than their customers' health and safety. Often, dangerous product victims do not have the financial resources to pay their medical bills and monthly expenses, let alone legal fees. This is why we don't charge for legal consultations and case reviews. We don't receive payment until you receive compensation for your losses.

With no upfront costs and no legal fees owed until you have money from the liable company, you have nothing to lose by working with us. Reach out today for a free consultation to discuss a potential hair relaxer lawsuit.

Trust LLN to Handle Your Hair Straightener Cancer-Related Lawsuit

If you or a loved one used chemical hair straighteners or relaxers and then received a uterine cancer diagnosis, we can help. We promise to provide the highest quality services as we guide you through the complicated product liability legal process. Let us help you pursue your legal options and find peace of mind.

Call 866-535-9515 today or complete our simple online form for a free consultation.